Lead Product(s): AUTO3, Pembrolizumab
Therapeutic Area: Oncology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2020
Initial data show encouraging clinical activity with manageable safety profile. No neurotoxicity observed to date in patients treated with AUTO3 + pembrolizumab.